Definition, classification, and adjacent boundaries
A melatonin ingredient is an active material manufactured and standardized by chemical synthesis, biosynthesis, or another permitted route with N-acetyl-5-methoxytryptamine as the target chemical entity, for use in medicines, health foods, dietary supplements, or other legally permitted products. Melatonin is an endogenous signal involved in circadian and sleep-phase regulation, but the source, purity, dose, release pattern, and timing of an exogenous ingredient determine actual exposure. “Naturally present in the human body” does not replace evaluation of safety, quality, and efficacy. Within WSIC, this entry is coded 6.1.1 under Industry Support / Research, Manufacturing and Supply Chain / Specialized Components and Materials.
Highly purified synthetic melatonin, microbially biosynthesized melatonin, and a melatonin-containing botanical extract are different materials. Melatonin commonly occurs at low concentration in plant tissue, and an extract also carries polyphenols, pigments, lipids, and other indoles. A “plant melatonin” label without actual melatonin content and complete composition cannot make the material equivalent to a purified ingredient or clinical study material. A plant containing tryptophan, 5-hydroxytryptophan, serotonin, or compounds that influence endogenous melatonin secretion does not thereby contain a quantifiable amount of melatonin.
A melatonin ingredient is not a melatonin finished product. Passing an incoming-ingredient test does not establish accurate dose, proper release, or clinical efficacy in a tablet, gummy, liquid, or modified-release dosage form. Melatonin is not the same substance as a melatonin-receptor agonist, sedative–hypnotic, antihistamine, or herbal sleep ingredient. Measurement of endogenous melatonin, a light intervention, and treatment with a finished melatonin product are adjacent but distinct questions; findings in one cannot be transferred without qualification to another.
Source route, chemical identity, and impurity profile
Ingredient identity should include the common and systematic chemical names, molecular formula and relative molecular mass, registry identifier, crystalline or other solid-state properties, particle size, and relevant solubility data, confirmed with a traceable reference standard. Chemical synthesis can begin with a methoxyindole or 5-methoxytryptamine intermediate and use side-chain construction, reduction, acetylation, and purification. Different routes create different residual starting materials, positional isomers, overreaction products, condensates, catalysts, and solvents. A high main-peak percentage alone does not establish control of route-specific impurities.
A biosynthetic route can proceed from tryptophan through 5-hydroxytryptophan, serotonin, and N-acetylserotonin or use engineered organisms, whole cells, or enzyme cascades. Production strain, genetic construct, cell bank, substrates, cofactors, medium, and downstream removal should be traceable, with controls for residual viable cells, host-cell protein, DNA, endotoxin, or other cellular material. Biological origin does not eliminate every risk; it shifts the expected impurity profile from chemical-route residues toward precursors, branch-pathway metabolites, and biological-process residues.
A botanical extract must state botanical species, plant part, origin, harvest and processing, extraction solvent, concentration ratio, carrier, and batch fingerprint. Because related indoles are structurally similar and the matrix is complex, melatonin, serotonin, tryptophan, and relevant precursors should be distinguished and separately quantified to prevent a coeluting peak from inflating the result. Regardless of source, impurity assessment should address specified related compounds, individual and total unknowns, residual solvents, elemental impurities, and applicable pesticides, mycotoxins, and allergens. “Natural” and “synthetic” are not quality grades.
Manufacturing, purification, and process control
Chemical manufacture should link raw-material identification, reaction stoichiometry, temperature, time, pH, catalytic or reduction conditions, extraction, washing, decolorization, crystallization, recrystallization, drying, and packaging to critical quality attributes. Endpoint control should observe both the target and critical intermediates rather than only total solids or yield. Mother-liquor reuse, solvent recovery, and rework can enrich difficult impurities and require predetermined cycle limits, mass balance, and comparability rules. Diluting an abnormal batch with a high-purity batch is not a substitute for deviation investigation.
Biomanufacturing additionally requires monitoring of strain identity and stability, adventitious organisms, bacteriophage, substrate consumption, intermediate accumulation, methyl or acetyl donors, dissolved oxygen, and fermentation endpoint. Downstream cell removal, adsorption, ion exchange, membrane separation, extraction, or crystallization should demonstrate recovery of the target and clearance of serotonin, N-acetylserotonin, tryptophan derivatives, and process residues. A change in host, genetic construct, medium, resin, membrane, solvent, or crystallization conditions can create a new impurity profile and belongs under formal change control.
Melatonin is sensitive to light and oxidative conditions and can form hydroxylated, ring-opened, or other oxidation products. Process exposure, hold times, solution pH, contact with metals, and lighting conditions should be controlled. Manufacturing areas also need to prevent cross-contamination with highly active medicines or hormonal materials and verify cleaning recovery. Final micronization, sieving, or blending changes particle size, electrostatic behavior, flow, and finished-product content uniformity. Those physical changes do not alter molecular identity but can materially affect delivery and release at low doses.
Analysis, specifications, and batch release
Identification can combine liquid-chromatographic retention, ultraviolet or fluorescence characteristics, mass spectrometry, infrared spectroscopy, and, when needed, nuclear-magnetic-resonance or solid-state analysis. Assay and related-substances testing should use a stability-indicating chromatographic method capable of separating serotonin, N-acetylserotonin, 5-methoxytryptamine, positional isomers, synthetic intermediates, and degradants. Complex botanical or multi-ingredient matrices commonly require more selective liquid chromatography–mass spectrometry. Method validation should cover specificity, recovery, linearity, precision, accuracy, quantitation limit, solution stability, and membrane-filter adsorption. Total indoles or nonspecific fluorescence cannot stand for melatonin.
An ingredient specification commonly covers appearance, identity, assay and its dried or as-is basis, related substances, water or loss on drying, residual solvents, elemental impurities, ash, particle size, and microbiological attributes. Source-specific tests can add catalysts, reaction reagents, biological-process residues, pesticides, mycotoxins, allergens, or a botanical fingerprint. Limits must be supported jointly by manufacturing capability, toxicology, compendial or legal requirements, and stability. A certificate of analysis should report numerical results, method version, and batch number, not merely “conforms to internal specification.”
The dose in one finished-product serving is often very small relative to the mass of the excipient blend, so weighing, geometric dilution, blending, transfer loss, and sampling error can create large variation. The ingredient supplier should provide particle-size, bulk-density, flow, and mixing information, but the finished-product manufacturer must still validate content uniformity, dissolution or release, distribution in gummies and liquids, and stability in the final package. A conforming ingredient assay does not establish an accurate label amount in the product. Any overage intended to compensate for expected loss requires stability and regulatory justification and cannot conceal an uncontrolled process.
Stability, dosage-form delivery, and safety
Stability programs should use stability-indicating methods to examine light, oxygen, temperature, humidity, pH, and time in the actual package and follow assay, critical degradants, moisture, color, and physical state. Transparent packaging, repeated air entry after opening, high water activity in a liquid or gummy, and coexistence with flavors, colors, or reducing components can change the outcome. Transport excursions, bulk hold time after opening, and retest period require supporting data. Storage statements such as “protect from light and keep tightly closed” cannot simply be copied from a supplier template.
Immediate-release, prolonged-release, biphasic, sublingual, and liquid dosage forms can have different concentration peaks and durations; common ingredient identity does not establish bioequivalence. Particle size, solid form, coating, excipients, food, and dosage form can alter dissolution and exposure. A prolonged-release claim requires a real release profile and appropriate human data. Circadian action also depends on administration relative to individual biological phase, and one clock time will not necessarily shift people with different sleep schedules in the same direction. An ingredient page should therefore not give one universal administration time.
Safety assessment should cover drowsiness, headache, dizziness, gastrointestinal symptoms, dream or mood changes, and next-day function and should consider potential interactions with alcohol, sedatives, anticoagulants, antihypertensives, immune-related medicines, and co-ingredients. Long-term use, pregnancy and breastfeeding, child development, older adults with multiple conditions, and impaired liver or kidney function require evidence matched to the use. Gummies and flavored products can be mistaken for candy by children. Packaging, child resistance, serving design, and storage at home are part of risk control and cannot be replaced by “low dose” or “natural hormone.”
Human evidence and boundaries of sleep claims
Melatonin can have a phase-shifting action and, under particular conditions, an effect on sleep initiation; those objectives must be distinguished. Jet lag, delayed sleep–wake phase, non-24-hour sleep–wake rhythm, general insomnia, and sleep problems comorbid with another condition differ in cause, endpoints, and strength of evidence. A result must be tied to ingredient quality, immediate or prolonged release, amount, timing relative to biological phase, treatment duration, population, and comparator. Evidence from one setting cannot be expanded to every experience of “poor sleep.”
Systematic reviews have reported statistically significant changes in sleep-onset latency, total sleep time, or subjective quality, but effects are generally small, studies are heterogeneous, and conclusions differ in clinical importance and age subgroup. Adult chronic-insomnia guidelines are cautious about or recommend against ordinary melatonin, while some jurisdictions and guidelines give different advice for a defined age group, prolonged-release product, or circadian-rhythm disorder. Statistical significance does not guarantee benefit to an individual, and questionnaires, sleep diaries, actigraphy, and polysomnography do not measure interchangeable constructs.
A sleep claim should rest on human evidence for the final dosage form and target population and report the primary endpoint, multiplicity, withdrawals, adverse events, and next-day alertness. Melatonin is not a universal way to mask sleep apnea, mania, an adverse drug effect, pain, shift-work fatigue, or dangerous sleepiness, and it does not replace comprehensive chronic-insomnia assessment or cognitive behavioral therapy. Use in children, driving, and safety-critical work particularly calls for professional judgment. Ingredient materials must not promise “absolutely safe because non-habit-forming,” “works in one night,” or “resets everyone's body clock.”
Regulation, procurement, and continued verification
The regulatory identity of melatonin differs substantially worldwide. It can be a prescription medicine, nonprescription medicine, dietary supplement, health-food ingredient, or a pharmacologically active substance not permitted in ordinary food. Each target market requires separate verification of source route, ingredient standard, product category, dosage form, daily amount, included and excluded populations, labeling, health claims, and medicinal indication. Permission to sell a supplement in one country does not permit addition to candy or beverages. Inclusion in a health-food ingredient catalogue does not turn melatonin into an ordinary food ingredient, and a registered functional claim cannot be rewritten as disease treatment.
A purchasing agreement should lock the manufacturing route and site, starting material or production system, assay, specified and unspecified impurities, residual solvents, elemental impurities, particle size, packaging, transport, and retest period and should require reference standards, method validation, batch certificates, stability support, change notification, and audit rights. A plant- or microbe-derived claim also requires verification of species or strain, extraction ratio or conversion route, carrier, and biological-process residues. A supplier's route change can alter impurities and stability even when main-component assay is unchanged and cannot automatically be treated as equivalent.
Continued verification should trend assay, related substances, particle size, water, and recovery and uniformity in customer products and incorporate label deviations, complaints, adverse events, unintended ingestion, recalls, and regulatory updates. Market surveys have found finished products whose measured content differed substantially from the label, showing why ingredient testing, formulation input, and finished-product release must form one loop. Public information should distinguish raw-material purity, dose per serving, release mechanism, and clinical evidence and should not let “natural sleep hormone,” “botanical extract,” or one passing assay replace complete proof of quality, safety, and sleep effect.